Research programme: cancer therapeutics - sanofi-aventis

Drug Profile

Research programme: cancer therapeutics - sanofi-aventis

Alternative Names: SAR 131675; SAR132885; SAR412988; SAR567530; SSR250411

Latest Information Update: 07 Dec 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Centromere protein E inhibitors; HSP90 heat-shock protein inhibitors; Vascular endothelial growth factor receptor 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Nov 2011 Pharmacodynamics data from a Preclinical trial in Cancer presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011)
  • 08 Jun 2010 Pharmacodynamics and adverse events data from a preclinical trial in Cancer presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)
  • 08 Jun 2010 Preclinical pharmacodynamics data in Solid tumours presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top